A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Blood Adv. 2020 Dec 8;4(23):6034-6038. doi: 10.1182/bloodadvances.2020003326.

Abstract

  1. Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition.

  2. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clone Cells
  • Glycine* / analogs & derivatives
  • Humans
  • Isocitrate Dehydrogenase
  • Janus Kinase 2 / genetics
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Pyridines*

Substances

  • Pyridines
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • JAK2 protein, human
  • Janus Kinase 2
  • ivosidenib
  • Glycine